From the Department of Health Services, Policy and Practice (T.Z.), Brown University School of Public Health, Providence, RI; Department of Medicine (H.T., F.Z., E.K., R.C.), Division of Neurology and Centre for Brain Health, University of British Columbia, Vancouver; Department of Medicine (J.D.F., V.B., T.C.), Department of Psychiatry (J.D.F.), and School of Nursing (T.C.), Dalhousie University; Nova Scotia Health Authority (J.D.F., V.B., K.S.), Halifax; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University; The Research Institute of the McGill University Health Centre (C.W.), Montreal, Quebec; Faculty of Rehabilitation Medicine (S.W.), University of Alberta, Edmonton; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.
To examine the association between physical comorbidities and disability progression in multiple sclerosis (MS).
We conducted a retrospective cohort study using linked health administrative and clinical databases in 2 Canadian provinces. Participants included adults with incident MS between 1990 and 2010 who entered the cohort at their MS symptom onset date. Comorbidity status was identified with validated algorithms for health administrative data and was measured during the 1 year before study entry and throughout the study period. The outcome was the Expanded Disability Status Scale (EDSS) score as recorded at each clinic visit. We used generalized estimating equations to examine the association between physical comorbidities and EDSS scores over time, adjusting for sex, age, cohort entry year, use of disease-modifying drugs, disease course, and socioeconomic status. Meta-analyses were used to estimate overall effects across the 2 provinces.
We identified 3,166 individuals with incident MS. Physical comorbidity was associated with disability; with each additional comorbidity, there was a mean increase in the EDSS score of 0.18 (95% confidence interval [CI] 0.09-0.28). Among specific comorbidities, the presence of ischemic heart disease (IHD) or epilepsy was associated with higher EDSS scores (IHD 0.31, 95% CI 0.01-0.61; epilepsy 0.68, 95% CI 0.11-1.26).
Physical comorbidities are associated with an apparent increase in MS disability progression. Appropriate management of comorbidities needs to be determined to optimize outcomes.
研究多发性硬化症(MS)患者的躯体合并症与残疾进展之间的相关性。
我们开展了一项回顾性队列研究,使用加拿大 2 个省份的健康管理和临床数据库进行分析。研究对象包括 1990 年至 2010 年间发病的多发性硬化症患者,他们在多发性硬化症症状发作日期进入队列。使用健康管理数据的验证算法确定合并症状态,并在研究入组前 1 年及整个研究期间进行测量。结局是每次就诊时记录的扩展残疾状况量表(EDSS)评分。我们使用广义估计方程,调整性别、年龄、入组年份、使用疾病修正药物、疾病病程和社会经济地位后,考察躯体合并症与 EDSS 评分随时间的变化关系。使用荟萃分析估计这 2 个省份的总体影响。
我们确定了 3166 名新发多发性硬化症患者。躯体合并症与残疾有关;每增加一种合并症,EDSS 评分平均增加 0.18(95%置信区间[CI]0.09-0.28)。在特定的合并症中,存在缺血性心脏病(IHD)或癫痫与更高的 EDSS 评分相关(IHD 0.31,95%CI 0.01-0.61;癫痫 0.68,95%CI 0.11-1.26)。
躯体合并症与多发性硬化症残疾进展明显相关。需要确定合并症的适当管理方法,以优化治疗结局。